Skip to main content

Table 2 Primary treatment outcomes

From: Effectiveness and safety of artemether–lumefantrine versus artesunate–amodiaquine for unsupervised treatment of uncomplicated falciparum malaria in patients of all age groups in Nanoro, Burkina Faso: a randomized open label trial

Treatment outcome AL, n = 333 (%) ASAQ, n = 327 (%) Difference (95 % CI) P-value
PCR unadjusted
 ACPR 159 (47.8) 219 (67.0) −0.19 (−26.62; −11.81) <0.00001
 TTF 174 (52.2) 108 (43.0)   
 ETF 2 (0.6) 3 (0.9)   
 LCF 47 (14.1) 18 (5.5)   
 LPF 125 (37.5) 87 (26.6)   
PCR adjusted
 ACPR 259 (77.8) 275 (84.1) −6.32 (−12.29; −0.34) 0.0389
 TTF 74 (22.2) 52 (15.9)   
 ETF 2 (0.6) 3 (0.9)   
 LCF 22 (6.6) 11 (3.4)   
 LPF 50 (15.0) 38 (11.6)